Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Research Abstract |
Volatile anesthetic sevoflurane, thiazolidinedione pioglitazone, and glucagon-like peptide 1 liraglutide administered before ischemia would prevent ischemia-reperfusion-induced liver damage, apoptosis, or survival rate. Non-alcoholic steatohepatitis (NASH) rats resulted in more ischemia-reperfusion-induced liver damage and decreased a survival rate as compared with normal rats. And the protective effects of sevoflurane, pioglitazone, and liraglutide have been inhibited in NASH rats. The combination sevoflurane and pioglitazone administered before ischemia would prevent ischemia-reperfusion-induced liver damage, apoptosis, or survival rate in NASH rats. This combination has better protection than sevoflurane, pioglitazone, and liraglutide alone in NASH rats.
|